SIM-0278

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameSIM-0278
Drug Alias NameIL2muFc(先声药业)ALM-223SIM0278
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionInterleukin-2 replacements
TargetsInterleukin-2
Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicDermatitis, Atopic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpainMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSimcere Pharmaceutical Group Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSimcere Pharmaceutical Co LtdAlmirall SaSimcere Pharmaceutical Group Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicDermatitis, Atopic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A